25 XP   0   0   10

Cardiff Oncology Inc
Buy, Hold or Sell?

Let's analyse Cardiff Oncology Inc together

PenkeI guess you are interested in Cardiff Oncology Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Cardiff Oncology Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Cardiff Oncology Inc

I send you an email if I find something interesting about Cardiff Oncology Inc.

Quick analysis of Cardiff Oncology Inc (30 sec.)










What can you expect buying and holding a share of Cardiff Oncology Inc? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
57.5%

What is your share worth?

Current worth
$1.56
Expected worth in 1 year
$0.74
How sure are you?
37.5%

+ What do you gain per year?

Total Gains per Share
$-0.82
Return On Investment
-18.7%

For what price can you sell your share?

Current Price per Share
$4.37
Expected price per share
$2.79 - $6.42
How sure are you?
50%

1. Valuation of Cardiff Oncology Inc (5 min.)




Live pricePrice per Share (EOD)

$4.37

Intrinsic Value Per Share

$-7.07 - $-6.31

Total Value Per Share

$-5.51 - $-4.75

2. Growth of Cardiff Oncology Inc (5 min.)




Is Cardiff Oncology Inc growing?

Current yearPrevious yearGrowGrow %
How rich?$69.7m$117.5m-$34.8m-42.2%

How much money is Cardiff Oncology Inc making?

Current yearPrevious yearGrowGrow %
Making money-$10.1m-$9.3m-$839.7k-8.3%
Net Profit Margin-8,933.4%-10,239.4%--

How much money comes from the company's main activities?

3. Financial Health of Cardiff Oncology Inc (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#437 / 1016

Most Revenue
#628 / 1016

Most Profit
#560 / 1016

Most Efficient
#944 / 1016

What can you expect buying and holding a share of Cardiff Oncology Inc? (5 min.)

Welcome investor! Cardiff Oncology Inc's management wants to use your money to grow the business. In return you get a share of Cardiff Oncology Inc.

What can you expect buying and holding a share of Cardiff Oncology Inc?

First you should know what it really means to hold a share of Cardiff Oncology Inc. And how you can make/lose money.

Speculation

The Price per Share of Cardiff Oncology Inc is $4.37. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Cardiff Oncology Inc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Cardiff Oncology Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $1.56. Based on the TTM, the Book Value Change Per Share is $-0.20 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.19 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Cardiff Oncology Inc.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.21-4.8%-0.23-5.3%-0.22-5.0%-0.17-3.8%-0.15-3.5%
Usd Book Value Change Per Share-0.18-4.1%-0.20-4.7%-0.19-4.4%0.071.5%0.030.6%
Usd Dividend Per Share0.000.0%0.000.0%0.000.1%0.030.6%0.081.9%
Usd Total Gains Per Share-0.18-4.1%-0.20-4.7%-0.19-4.3%0.092.2%0.112.5%
Usd Price Per Share1.48-1.50-1.91-4.47-3.93-
Price to Earnings Ratio-1.77--1.62--2.17--8.20--8.08-
Price-to-Total Gains Ratio-8.19--7.35--10.03--36.36--32.53-
Price to Book Ratio0.95-0.82-0.72-5.25-7.02-
Price-to-Total Gains Ratio-8.19--7.35--10.03--36.36--32.53-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share4.37
Number of shares228
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.03
Usd Book Value Change Per Share-0.200.07
Usd Total Gains Per Share-0.200.09
Gains per Quarter (228 shares)-46.6721.54
Gains per Year (228 shares)-186.6886.15
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-187-197256176
20-374-38451122162
30-560-57176183248
40-747-758101244334
51-934-945126304420
61-1121-1132152365506
71-1308-1319177426592
81-1494-1506202487678
91-1681-1693227548764
101-1868-1880253609850

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.020.00.00.0%0.040.00.00.0%1.054.00.01.8%
Book Value Change Per Share0.04.00.00.0%2.010.00.016.7%6.014.00.030.0%11.029.00.027.5%14.037.04.025.5%
Dividend per Share3.00.01.075.0%9.00.03.075.0%13.00.07.065.0%23.00.017.057.5%23.00.032.041.8%
Total Gains per Share0.04.00.00.0%2.010.00.016.7%6.014.00.030.0%15.025.00.037.5%18.033.04.032.7%

Fundamentals of Cardiff Oncology Inc

About Cardiff Oncology Inc

Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.

Fundamental data was last updated by Penke on 2024-04-11 05:00:04.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is cheap.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Cardiff Oncology Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Cardiff Oncology Inc earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Cardiff Oncology Inc to the Biotechnology industry mean.
  • A Net Profit Margin of -5,985.3% means that $-59.85 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Cardiff Oncology Inc:

  • The MRQ is -5,985.3%. The company is making a huge loss. -2
  • The TTM is -8,933.4%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-5,985.3%TTM-8,933.4%+2,948.2%
TTM-8,933.4%YOY-10,239.4%+1,306.0%
TTM-8,933.4%5Y-7,573.7%-1,359.7%
5Y-7,573.7%10Y-7,439.2%-134.5%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-5,985.3%-199.6%-5,785.7%
TTM-8,933.4%-213.0%-8,720.4%
YOY-10,239.4%-279.3%-9,960.1%
5Y-7,573.7%-438.4%-7,135.3%
10Y-7,439.2%-605.5%-6,833.7%
1.1.2. Return on Assets

Shows how efficient Cardiff Oncology Inc is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Cardiff Oncology Inc to the Biotechnology industry mean.
  • -11.4% Return on Assets means that Cardiff Oncology Inc generated $-0.11 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Cardiff Oncology Inc:

  • The MRQ is -11.4%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -10.9%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-11.4%TTM-10.9%-0.5%
TTM-10.9%YOY-7.3%-3.6%
TTM-10.9%5Y-14.0%+3.1%
5Y-14.0%10Y-17.9%+3.9%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-11.4%-13.5%+2.1%
TTM-10.9%-12.9%+2.0%
YOY-7.3%-11.8%+4.5%
5Y-14.0%-14.1%+0.1%
10Y-17.9%-16.0%-1.9%
1.1.3. Return on Equity

Shows how efficient Cardiff Oncology Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Cardiff Oncology Inc to the Biotechnology industry mean.
  • -13.4% Return on Equity means Cardiff Oncology Inc generated $-0.13 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Cardiff Oncology Inc:

  • The MRQ is -13.4%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -12.4%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-13.4%TTM-12.4%-1.0%
TTM-12.4%YOY-7.9%-4.5%
TTM-12.4%5Y-20.6%+8.2%
5Y-20.6%10Y-36.1%+15.5%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-13.4%-16.9%+3.5%
TTM-12.4%-16.1%+3.7%
YOY-7.9%-15.1%+7.2%
5Y-20.6%-19.9%-0.7%
10Y-36.1%-20.9%-15.2%

1.2. Operating Efficiency of Cardiff Oncology Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Cardiff Oncology Inc is operating .

  • Measures how much profit Cardiff Oncology Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Cardiff Oncology Inc to the Biotechnology industry mean.
  • An Operating Margin of -6,623.1% means the company generated $-66.23  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Cardiff Oncology Inc:

  • The MRQ is -6,623.1%. The company is operating very inefficient. -2
  • The TTM is -10,030.3%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-6,623.1%TTM-10,030.3%+3,407.2%
TTM-10,030.3%YOY-10,862.0%+831.8%
TTM-10,030.3%5Y-7,992.7%-2,037.6%
5Y-7,992.7%10Y-7,627.4%-365.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-6,623.1%-295.1%-6,328.0%
TTM-10,030.3%-225.8%-9,804.5%
YOY-10,862.0%-288.4%-10,573.6%
5Y-7,992.7%-477.4%-7,515.3%
10Y-7,627.4%-625.6%-7,001.8%
1.2.2. Operating Ratio

Measures how efficient Cardiff Oncology Inc is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 67.23 means that the operating costs are $67.23 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Cardiff Oncology Inc:

  • The MRQ is 67.231. The company is inefficient in keeping operating costs low. -1
  • The TTM is 101.990. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ67.231TTM101.990-34.759
TTM101.990YOY110.040-8.050
TTM101.9905Y82.202+19.789
5Y82.20210Y268.572-186.371
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ67.2313.090+64.141
TTM101.9903.264+98.726
YOY110.0403.783+106.257
5Y82.2025.679+76.523
10Y268.5727.894+260.678

1.3. Liquidity of Cardiff Oncology Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Cardiff Oncology Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 7.41 means the company has $7.41 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Cardiff Oncology Inc:

  • The MRQ is 7.415. The company is very able to pay all its short-term debts. +2
  • The TTM is 9.843. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ7.415TTM9.843-2.428
TTM9.843YOY16.045-6.202
TTM9.8435Y13.075-3.232
5Y13.07510Y9.821+3.254
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ7.4153.914+3.501
TTM9.8434.220+5.623
YOY16.0455.388+10.657
5Y13.0756.045+7.030
10Y9.8216.406+3.415
1.3.2. Quick Ratio

Measures if Cardiff Oncology Inc is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Cardiff Oncology Inc to the Biotechnology industry mean.
  • A Quick Ratio of 12.29 means the company can pay off $12.29 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Cardiff Oncology Inc:

  • The MRQ is 12.287. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 17.051. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ12.287TTM17.051-4.764
TTM17.051YOY28.188-11.136
TTM17.0515Y21.556-4.505
5Y21.55610Y14.269+7.287
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ12.2873.572+8.715
TTM17.0513.998+13.053
YOY28.1885.390+22.798
5Y21.5565.969+15.587
10Y14.2696.287+7.982

1.4. Solvency of Cardiff Oncology Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Cardiff Oncology Inc assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Cardiff Oncology Inc to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.15 means that Cardiff Oncology Inc assets are financed with 14.6% credit (debt) and the remaining percentage (100% - 14.6%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Cardiff Oncology Inc:

  • The MRQ is 0.146. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.118. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.146TTM0.118+0.028
TTM0.118YOY0.079+0.039
TTM0.1185Y0.171-0.053
5Y0.17110Y0.322-0.151
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1460.336-0.190
TTM0.1180.334-0.216
YOY0.0790.269-0.190
5Y0.1710.366-0.195
10Y0.3220.390-0.068
1.4.2. Debt to Equity Ratio

Measures if Cardiff Oncology Inc is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Cardiff Oncology Inc to the Biotechnology industry mean.
  • A Debt to Equity ratio of 17.1% means that company has $0.17 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Cardiff Oncology Inc:

  • The MRQ is 0.171. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.134. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.171TTM0.134+0.036
TTM0.134YOY0.086+0.048
TTM0.1345Y0.256-0.121
5Y0.25610Y0.684-0.428
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1710.382-0.211
TTM0.1340.396-0.262
YOY0.0860.335-0.249
5Y0.2560.434-0.178
10Y0.6840.465+0.219

2. Market Valuation of Cardiff Oncology Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Cardiff Oncology Inc generates.

  • Above 15 is considered overpriced but always compare Cardiff Oncology Inc to the Biotechnology industry mean.
  • A PE ratio of -1.77 means the investor is paying $-1.77 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Cardiff Oncology Inc:

  • The EOD is -5.228. Based on the earnings, the company is expensive. -2
  • The MRQ is -1.770. Based on the earnings, the company is expensive. -2
  • The TTM is -1.620. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-5.228MRQ-1.770-3.457
MRQ-1.770TTM-1.620-0.151
TTM-1.620YOY-2.168+0.548
TTM-1.6205Y-8.200+6.580
5Y-8.20010Y-8.075-0.124
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-5.228-2.259-2.969
MRQ-1.770-2.569+0.799
TTM-1.620-2.664+1.044
YOY-2.168-4.120+1.952
5Y-8.200-6.258-1.942
10Y-8.075-6.171-1.904
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Cardiff Oncology Inc:

  • The EOD is -6.829. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -2.313. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -2.135. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-6.829MRQ-2.313-4.516
MRQ-2.313TTM-2.135-0.178
TTM-2.135YOY-2.496+0.361
TTM-2.1355Y-10.306+8.171
5Y-10.30610Y-9.015-1.291
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-6.829-2.924-3.905
MRQ-2.313-3.246+0.933
TTM-2.135-3.488+1.353
YOY-2.496-5.620+3.124
5Y-10.306-8.315-1.991
10Y-9.015-8.826-0.189
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Cardiff Oncology Inc is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 0.95 means the investor is paying $0.95 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Cardiff Oncology Inc:

  • The EOD is 2.800. Based on the equity, the company is underpriced. +1
  • The MRQ is 0.948. Based on the equity, the company is cheap. +2
  • The TTM is 0.817. Based on the equity, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD2.800MRQ0.948+1.851
MRQ0.948TTM0.817+0.131
TTM0.817YOY0.716+0.101
TTM0.8175Y5.253-4.436
5Y5.25310Y7.016-1.762
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD2.8001.851+0.949
MRQ0.9482.090-1.142
TTM0.8172.095-1.278
YOY0.7162.844-2.128
5Y5.2533.466+1.787
10Y7.0163.815+3.201
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Cardiff Oncology Inc.

3.1. Institutions holding Cardiff Oncology Inc

Institutions are holding 15.171% of the shares of Cardiff Oncology Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31Vanguard Group Inc4.27910.00011911789-31129-1.6022
2023-09-30LAURION CAPITAL MANAGEMENT LP1.61630.006172210000
2023-12-31BlackRock Inc1.60370716490-1101-0.1534
2023-12-31Geode Capital Management, LLC0.94930.0001424106317998.1056
2023-12-31Mccormack Advisors International0.8490.007437931015456168.7705
2023-12-31State Street Corporation0.3132013994500
2023-12-31Blair William & Co0.2910.0007130000-500-0.3831
2023-12-31Renaissance Technologies Corp0.26050.0003116400-37600-24.4156
2023-12-31Northern Trust Corp0.159807138600
2023-09-30Jacobs Levy Equity Management, Inc.0.14670.000565558-31495-32.4513
2023-12-31Elkhorn Partners Limited Partnership0.14660.0671655002050045.5556
2023-12-31Capstone Investment Advisors, LLC0.11460.00025119000
2023-12-31Bank of America Corp0.111404978800
2023-12-31Two Sigma Advisers, LLC0.08770.000139200-1800-4.3902
2023-12-31T. Rowe Price Associates, Inc.0.081703650000
2023-12-31XTX Topco Ltd0.07490.010833453334530
2023-12-31Callan Capital, LLC0.06970.00443114700
2023-12-31Two Sigma Investments LLC0.06860.000130667-22600-42.4278
2023-12-31Creative Planning Inc0.05710.000125500-33251-56.5965
2023-12-31Susquehanna International Group, LLP0.051022781-57391-71.5848
Total 11.33190.0985062810+23446+0.5%

3.2. Funds holding Cardiff Oncology Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-02-29Vanguard Total Stock Mkt Idx Inv2.80840.0001125471700
2024-02-29Vanguard Institutional Extnd Mkt Idx Tr1.32220.00159070700
2024-02-29Fidelity Extended Market Index0.53010.0011236853-1148-0.4824
2023-09-30BlackRock Extended Mkt Composite0.32410.001414478800
2024-03-31BlackRock Extended Equity Market K0.21190.003594658-31657-25.0619
2024-03-28iShares Micro-Cap ETF0.19440.05058687000
2024-02-29Fidelity Total Market Index0.16850.00027526000
2024-02-29Fidelity Series Total Market Index0.11750.00015248600
2023-12-31T. Rowe Price U.S. Equities Tr0.08170.00063650000
2023-12-31NT Ext Equity Mkt Idx Fd - L0.07830.00093496400
2023-12-31Northern Trust Extended Eq Market Idx0.07830.00093496400
2023-12-31NT Ext Equity Mkt Idx Fd - NL0.07340.00083281100
2023-10-31Vanguard Instl Ttl Stck Mkt Idx Tr0.06210.000127727-1258119-97.8437
2024-02-29Vanguard Instl Ttl Stk Mkt Idx InstlPls0.06210.00022772700
2024-02-29Spartan Total Market Index Pool E0.06160.00022754200
2023-12-31NT Ext Equity Mkt Idx Fd - DC - NL - T20.0590.000826352490.1863
2024-02-29Vanguard Balanced Index Inv0.05550.00012479700
2024-02-29Fidelity Nasdaq Composite Index0.05330.00032381200
2024-03-29Avantis US Small Cap Equity ETF0.04810.01142149800
2024-02-29Schwab Total Stock Market Index0.03670.00011639900
Total 6.42720.07432871432-1290875-45.0%

3.3. Insider Transactions

Insiders are holding 7.557% of the shares of Cardiff Oncology Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2023-12-19Gary W PaceBUY300001.37

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Cardiff Oncology Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.181-0.205+13%-0.191+5%0.067-371%0.028-756%
Book Value Per Share--1.5611.850-16%2.631-41%1.749-11%1.094+43%
Current Ratio--7.4159.843-25%16.045-54%13.075-43%9.821-25%
Debt To Asset Ratio--0.1460.118+24%0.079+84%0.171-15%0.322-55%
Debt To Equity Ratio--0.1710.134+27%0.086+98%0.256-33%0.684-75%
Dividend Per Share--0.0000.000+100%0.002-89%0.028-99%0.081-100%
Eps---0.209-0.232+11%-0.217+4%-0.165-21%-0.153-27%
Free Cash Flow Per Share---0.160-0.176+10%-0.195+22%-0.133-17%-0.126-21%
Free Cash Flow To Equity Per Share---0.160-0.176+10%-0.195+22%0.090-277%9.207-102%
Gross Profit Margin--1.8131.203+51%1.000+81%1.041+74%1.117+62%
Intrinsic Value_10Y_max---6.306--------
Intrinsic Value_10Y_min---7.069--------
Intrinsic Value_1Y_max---0.523--------
Intrinsic Value_1Y_min---0.679--------
Intrinsic Value_3Y_max---1.654--------
Intrinsic Value_3Y_min---2.077--------
Intrinsic Value_5Y_max---2.885--------
Intrinsic Value_5Y_min---3.506--------
Market Cap195239364.000+66%66122256.00066904107.000-1%85110066.000-22%199684745.400-67%175626073.200-62%
Net Profit Margin---59.853-89.334+49%-102.394+71%-75.737+27%-74.392+24%
Operating Margin---66.231-100.303+51%-108.620+64%-79.927+21%-76.274+15%
Operating Ratio--67.231101.990-34%110.040-39%82.202-18%268.572-75%
Pb Ratio2.800+66%0.9480.817+16%0.716+32%5.253-82%7.016-86%
Pe Ratio-5.228-195%-1.770-1.620-9%-2.168+22%-8.200+363%-8.075+356%
Price Per Share4.370+66%1.4801.498-1%1.905-22%4.470-67%3.931-62%
Price To Free Cash Flow Ratio-6.829-195%-2.313-2.135-8%-2.496+8%-10.306+346%-9.015+290%
Price To Total Gains Ratio-24.175-195%-8.188-7.350-10%-10.034+23%-36.355+344%-32.529+297%
Quick Ratio--12.28717.051-28%28.188-56%21.556-43%14.269-14%
Return On Assets---0.114-0.109-5%-0.073-36%-0.140+23%-0.179+57%
Return On Equity---0.134-0.124-7%-0.079-41%-0.206+54%-0.361+169%
Total Gains Per Share---0.181-0.205+13%-0.188+4%0.094-291%0.109-266%
Usd Book Value--69739000.00082662000.000-16%117532750.000-41%78159193.450-11%48883666.900+43%
Usd Book Value Change Per Share---0.181-0.205+13%-0.191+5%0.067-371%0.028-756%
Usd Book Value Per Share--1.5611.850-16%2.631-41%1.749-11%1.094+43%
Usd Dividend Per Share--0.0000.000+100%0.002-89%0.028-99%0.081-100%
Usd Eps---0.209-0.232+11%-0.217+4%-0.165-21%-0.153-27%
Usd Free Cash Flow---7147000.000-7867250.000+10%-8706500.000+22%-5954106.250-17%-5621907.725-21%
Usd Free Cash Flow Per Share---0.160-0.176+10%-0.195+22%-0.133-17%-0.126-21%
Usd Free Cash Flow To Equity Per Share---0.160-0.176+10%-0.195+22%0.090-277%9.207-102%
Usd Market Cap195239364.000+66%66122256.00066904107.000-1%85110066.000-22%199684745.400-67%175626073.200-62%
Usd Price Per Share4.370+66%1.4801.498-1%1.905-22%4.470-67%3.931-62%
Usd Profit---9337000.000-10153000.000+9%-9313250.0000%-7093811.050-24%-6606140.425-29%
Usd Revenue--156000.000122000.000+28%96500.000+62%102184.000+53%97536.125+60%
Usd Total Gains Per Share---0.181-0.205+13%-0.188+4%0.094-291%0.109-266%
 EOD+5 -3MRQTTM+22 -14YOY+18 -185Y+12 -2410Y+15 -21

4.2. Fundamental Score

Let's check the fundamental score of Cardiff Oncology Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-5.228
Price to Book Ratio (EOD)Between0-12.800
Net Profit Margin (MRQ)Greater than0-59.853
Operating Margin (MRQ)Greater than0-66.231
Quick Ratio (MRQ)Greater than112.287
Current Ratio (MRQ)Greater than17.415
Debt to Asset Ratio (MRQ)Less than10.146
Debt to Equity Ratio (MRQ)Less than10.171
Return on Equity (MRQ)Greater than0.15-0.134
Return on Assets (MRQ)Greater than0.05-0.114
Total4/10 (40.0%)

4.3. Technical Score

Let's check the technical score of Cardiff Oncology Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5041.806
Ma 20Greater thanMa 505.439
Ma 50Greater thanMa 1003.954
Ma 100Greater thanMa 2002.711
OpenGreater thanClose4.430
Total4/5 (80.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2022-12-312023-03-312023-06-302023-09-302023-12-31
Income Tax Expense  -695-134-829-224-1,053-15-1,0684,0182,950



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets81,637
Total Liabilities11,898
Total Stockholder Equity69,739
 As reported
Total Liabilities 11,898
Total Stockholder Equity+ 69,739
Total Assets = 81,637

Assets

Total Assets81,637
Total Current Assets77,412
Long-term Assets4,225
Total Current Assets
Cash And Cash Equivalents 21,655
Short-term Investments 53,168
Net Receivables 288
Other Current Assets 2,301
Total Current Assets  (as reported)77,412
Total Current Assets  (calculated)77,412
+/-0
Long-term Assets
Property Plant Equipment 2,946
Long-term Assets Other 1,279
Long-term Assets  (as reported)4,225
Long-term Assets  (calculated)4,225
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities10,440
Long-term Liabilities1,458
Total Stockholder Equity69,739
Total Current Liabilities
Short-term Debt 691
Accounts payable 1,966
Other Current Liabilities 7,783
Total Current Liabilities  (as reported)10,440
Total Current Liabilities  (calculated)10,440
+/-0
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt1,458
Long-term Liabilities  (as reported)1,458
Long-term Liabilities  (calculated)1,458
+/-0
Total Stockholder Equity
Common Stock4
Retained Earnings -339,541
Accumulated Other Comprehensive Income -67
Other Stockholders Equity 409,343
Total Stockholder Equity (as reported)69,739
Total Stockholder Equity (calculated)69,739
+/-0
Other
Capital Stock4
Cash and Short Term Investments 74,823
Common Stock Shares Outstanding 44,677
Liabilities and Stockholders Equity 81,637
Net Debt -19,506
Net Invested Capital 69,739
Net Working Capital 66,972
Property Plant and Equipment Gross 6,698
Short Long Term Debt Total 2,149



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-312006-09-302006-06-302006-03-312005-09-302005-06-302005-03-312003-09-302003-06-302003-03-31
> Total Assets 
0
2
2
-887
-2,111
-3,673
2,713
2,005
645
0
0
0
0
0
360
490
1,039
1,182
9,952
8,571
11,665
11,665
9,625
29,151
27,156
24,459
36,193
32,762
28,897
45,832
43,644
77,023
71,446
66,009
56,723
53,004
43,950
33,925
12,561
12,218
12,285
10,409
21,768
17,921
14,172
14,533
13,868
11,922
13,087
11,815
30,129
39,450
134,727
129,573
143,734
141,312
149,544
139,204
131,261
123,631
116,191
106,549
97,455
88,452
81,637
81,63788,45297,455106,549116,191123,631131,261139,204149,544141,312143,734129,573134,72739,45030,12911,81513,08711,92213,86814,53314,17217,92121,76810,40912,28512,21812,56133,92543,95053,00456,72366,00971,44677,02343,64445,83228,89732,76236,19324,45927,15629,1519,62511,66511,6658,5719,9521,1821,039490360000006452,0052,713-3,673-2,111-887220
   > Total Current Assets 
0
2
2
-887
-2,111
-3,673
2,544
1,719
492
0
0
0
0
0
140
290
842
706
9,440
8,001
11,048
10,820
8,524
27,998
26,069
23,263
35,030
31,574
27,294
44,473
41,902
74,818
68,381
60,892
51,620
47,978
38,950
29,729
8,655
8,552
9,469
7,840
19,643
16,044
12,765
12,337
11,820
9,977
11,354
10,283
28,819
38,189
133,356
128,570
142,871
137,769
146,127
135,806
127,414
119,755
111,284
101,753
92,731
83,905
77,412
77,41283,90592,731101,753111,284119,755127,414135,806146,127137,769142,871128,570133,35638,18928,81910,28311,3549,97711,82012,33712,76516,04419,6437,8409,4698,5528,65529,72938,95047,97851,62060,89268,38174,81841,90244,47327,29431,57435,03023,26326,06927,9988,52410,82011,0488,0019,440706842290140000004921,7192,544-3,673-2,111-887220
       Cash And Cash Equivalents 
0
2
2
-887
-2,111
-3,673
2,500
1,686
474
0
0
0
0
0
20
160
700
587
9,304
7,815
10,820
10,820
8,302
27,799
25,837
22,871
34,674
31,164
27,294
43,996
41,294
74,150
67,493
59,989
22,579
22,569
37,893
10,183
7,784
7,434
8,226
6,657
18,486
15,066
11,453
11,330
10,791
9,032
10,195
9,277
27,755
36,405
130,981
14,662
10,581
13,165
11,943
20,052
20,965
18,717
16,347
15,017
19,369
15,233
21,655
21,65515,23319,36915,01716,34718,71720,96520,05211,94313,16510,58114,662130,98136,40527,7559,27710,1959,03210,79111,33011,45315,06618,4866,6578,2267,4347,78410,18337,89322,56922,57959,98967,49374,15041,29443,99627,29431,16434,67422,87125,83727,7998,30210,82010,8207,8159,30458770016020000004741,6862,500-3,673-2,111-887220
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
28,005
24,377
23,978
18,620
0
0
0
0
32
0
0
0
0
0
0
0
0
0
0
110,922
129,470
120,882
128,878
109,310
101,041
95,586
88,920
81,951
70,059
66,130
53,168
53,16866,13070,05981,95188,92095,586101,041109,310128,878120,882129,470110,922000000000032000018,62023,97824,37728,0050000000000000000000000000000000000
       Net Receivables 
0
0
0
0
0
0
12
0
0
0
0
0
0
0
0
90
99
77
106
128
168
168
57
70
79
129
60
62
57
59
100
67
99
62
159
85
100
80
157
178
77
114
124
129
168
116
122
152
204
106
109
204
320
242
308
395
535
447
551
650
771
676
161
198
288
288198161676771650551447535395308242320204109106204152122116168129124114771781578010085159629967100595762601297970571681681281067799900000000012000000
       Other Current Assets 
0
0
0
0
0
0
32
34
18
0
0
0
0
0
120
40
43
42
30
57
0
60
165
129
153
262
296
348
369
418
508
601
789
841
878
946
957
846
714
939
1,166
1,068
1,002
849
1,144
891
907
793
955
899
955
1,579
2,055
2,744
2,512
3,327
4,771
5,997
4,857
4,802
5,246
4,109
3,142
2,344
2,301
2,3012,3443,1424,1095,2464,8024,8575,9974,7713,3272,5122,7442,0551,5799558999557939078911,1448491,0021,0681,166939714846957946878841789601508418369348296262153129165600573042434012000000183432000000
   > Long-term Assets 
0
0
0
0
0
0
169
286
153
0
0
0
0
0
220
200
197
476
512
570
617
845
1,102
1,152
1,087
1,196
1,164
1,188
1,603
1,359
1,742
2,205
3,065
5,117
5,103
5,026
5,000
4,196
3,906
3,666
2,816
2,569
2,125
1,877
1,407
2,196
2,048
1,946
1,733
1,532
1,310
1,262
1,371
1,003
863
3,543
3,417
3,398
3,847
3,876
4,907
4,796
4,724
4,547
4,225
4,2254,5474,7244,7964,9073,8763,8473,3983,4173,5438631,0031,3711,2621,3101,5321,7331,9462,0482,1961,4071,8772,1252,5692,8163,6663,9064,1965,0005,0265,1035,1173,0652,2051,7421,3591,6031,1881,1641,1961,0871,1521,10284561757051247619720022000000153286169000000
       Property Plant Equipment 
0
0
0
0
0
0
113
230
97
0
0
0
0
0
30
30
23
114
149
208
255
255
571
740
751
860
817
841
840
1,023
1,379
1,842
2,691
4,746
4,732
4,655
3,827
3,567
3,322
3,127
2,426
2,224
1,804
1,628
1,304
2,109
1,913
1,775
1,575
1,376
1,157
1,106
967
765
600
3,400
3,178
3,210
3,662
3,692
3,520
3,435
3,334
3,160
2,946
2,9463,1603,3343,4353,5203,6923,6623,2103,1783,4006007659671,1061,1571,3761,5751,7751,9132,1091,3041,6281,8042,2242,4263,1273,3223,5673,8274,6554,7324,7462,6911,8421,3791,0238408418178607517405712552552081491142330300000097230113000000
       Other Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
103
87
135
171
158
156
153
156
404
238
263
143
239
188
185
184
1,387
0
1,390
0
0
001,39001,3871841851882391432632384041561531561581711358710300000000000000000000000000000000000000000000
> Total Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
5,560
4,130
5,271
5,516
4,462
3,596
9,496
9,496
12,096
8,012
6,764
6,706
18,864
20,409
20,548
22,270
25,525
22,164
22,745
24,850
24,150
26,229
24,182
23,245
9,050
8,273
5,779
5,729
4,291
3,941
4,088
4,847
5,020
5,266
5,776
5,672
5,745
5,928
6,570
4,756
4,816
7,768
9,127
9,102
10,787
10,419
9,848
10,046
10,876
10,625
11,898
11,89810,62510,87610,0469,84810,41910,7879,1029,1277,7684,8164,7566,5705,9285,7455,6725,7765,2665,0204,8474,0883,9414,2915,7295,7798,2739,05023,24524,18226,22924,15024,85022,74522,16425,52522,27020,54820,40918,8646,7066,7648,01212,0969,4969,4963,5964,4625,5165,2714,1305,56000000000000000
   > Total Current Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
3,420
1,150
1,430
1,533
1,236
758
730
730
1,462
1,361
2,009
2,032
1,979
3,122
4,489
5,305
4,950
6,969
8,202
10,122
10,889
6,565
7,797
8,958
7,462
5,082
3,946
3,854
3,218
2,667
2,965
3,285
3,694
4,171
4,782
4,881
4,962
5,442
6,119
4,479
4,579
5,042
6,559
6,664
8,481
8,245
7,808
8,148
9,123
9,018
10,440
10,4409,0189,1238,1487,8088,2458,4816,6646,5595,0424,5794,4796,1195,4424,9624,8814,7824,1713,6943,2852,9652,6673,2183,8543,9465,0827,4628,9587,7976,56510,88910,1228,2026,9694,9505,3054,4893,1221,9792,0322,0091,3611,4627307307581,2361,5331,4301,1503,42000000000000000
       Short-term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2,340
0
0
0
0
0
0
0
63
148
198
201
0
753
1,899
3,065
2,320
3,745
5,226
5,850
6,147
801
2,360
3,873
1,645
1,488
1,332
1,175
0
0
0
796
816
836
866
871
948
1,189
860
635
402
594
551
665
670
674
675
679
683
688
691
6916886836796756746706655515944026358601,1899488718668368167960001,1751,3321,4881,6453,8732,3608016,1475,8505,2263,7452,3203,0651,89975302011981486300000002,34000000000000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
71
305
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000003057100000000000000000000000000000000000000000000000000
       Accounts payable 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
730
750
928
947
531
140
0
730
298
159
287
427
380
462
2,590
485
1,111
1,100
1,041
1,297
1,115
925
1,131
968
603
675
825
652
565
476
665
467
526
492
656
599
1,156
610
1,366
803
543
396
1,439
1,261
1,522
1,425
1,956
2,914
2,939
2,179
1,966
1,9662,1792,9392,9141,9561,4251,5221,2611,4393965438031,3666101,1565996564925264676654765656528256756039681,1319251,1151,2971,0411,1001,1114852,590462380427287159298730014053194792875073000000000000000
       Other Current Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
350
400
502
586
705
618
0
853
1,101
1,054
1,524
1,404
1,600
1,908
1,842
1,756
1,519
2,124
1,934
2,974
3,627
4,839
4,307
4,116
5,215
2,918
1,789
2,027
2,653
2,190
2,300
2,022
2,352
2,842
3,260
3,412
2,858
3,643
42
42
42
42
42
4,738
6,289
6,146
5,177
4,555
5,501
6,151
7,783
7,7836,1515,5014,5555,1776,1466,2894,73842424242423,6432,8583,4123,2602,8422,3522,0222,3002,1902,6532,0271,7892,9185,2154,1164,3074,8393,6272,9741,9342,1241,5191,7561,8421,9081,6001,4041,5241,0541,101853061870558650240035000000000000000
   > Long-term Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2,140
2,980
3,841
3,983
3,227
2,838
8,766
8,766
10,634
6,652
4,755
4,674
16,885
17,286
16,059
16,964
20,575
15,195
14,543
14,728
13,261
19,665
16,385
14,287
1,588
3,191
1,833
1,876
1,073
1,274
1,123
1,562
1,326
1,096
994
791
783
486
451
277
237
2,726
2,568
2,438
2,306
2,174
2,040
1,898
1,753
1,607
1,458
1,4581,6071,7531,8982,0402,1742,3062,4382,5682,7262372774514867837919941,0961,3261,5621,1231,2741,0731,8761,8333,1911,58814,28716,38519,66513,26114,72814,54315,19520,57516,96416,05917,28616,8854,6744,7556,65210,6348,7668,7662,8383,2273,9833,8412,9802,14000000000000000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
323
275
14,703
13,979
13,053
12,012
12,882
11,519
11,246
10,373
9,031
0
14,176
12,700
0
0
0
0
0
0
0
0
0
0
0
0
234
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000023400000000000012,70014,17609,03110,37311,24611,51912,88212,01213,05313,97914,703275323000000000000000000000000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
18
5
132
141
119
279
441
269
231
35
0
0
0
0
0
0
0
0
0
000000000352312694412791191411325180000000000000000000000000000000000000000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
4,432
4,399
2,182
3,211
3,006
4,953
7,693
3,676
3,297
2,763
2,710
0
2,209
1,587
1,588
3,191
1,833
1,876
1,073
1,274
1,123
42
18
5
4
2
46
190
285
78
17
5
0
0
0
0
0
0
0
0
0
000000000517782851904624518421,1231,2741,0731,8761,8333,1911,5881,5872,20902,7102,7633,2973,6767,6934,9533,0063,2112,1824,3994,432000000000000000000000000
> Total Stockholder Equity
0
0
0
3,154
5,448
5,448
2,102
1,365
25
0
0
0
0
0
-5,210
-3,640
-4,231
-4,334
5,489
4,975
0
2,169
-2,471
21,138
20,392
17,753
17,329
12,354
8,349
23,563
18,119
54,858
48,701
41,159
32,573
26,774
19,768
10,680
3,511
3,945
6,506
4,679
17,477
13,980
10,084
9,686
8,848
6,656
7,311
6,143
24,384
33,523
128,158
124,817
138,918
133,544
140,417
130,102
120,474
113,212
106,343
96,503
86,579
77,827
69,739
69,73977,82786,57996,503106,343113,212120,474130,102140,417133,544138,918124,817128,15833,52324,3846,1437,3116,6568,8489,68610,08413,98017,4774,6796,5063,9453,51110,68019,76826,77432,57341,15948,70154,85818,11923,5638,34912,35417,32917,75320,39221,138-2,4712,16904,9755,489-4,334-4,231-3,640-5,21000000251,3652,1025,4485,4483,154000
   Common Stock
0
0
0
3,154
2,677
2,677
2
2
2
0
0
0
0
0
10
10
6
7
1
1
0
2
2
2
2
2
2
2
2
2
2
3
3
3
3
3
3
3
3
4
5
6
7
8
8
8
8
8
8
9
10
10
4
4
4
4
4
4
4
4
4
4
4
4
4
4444444444444101098888887654333333332222222222011761010000002222,6772,6773,154000
   Retained Earnings Total Equity00-320,473-309,323-298,100-289,835-281,2580-259,810-250,362-243,443-236,680-231,495-224,892-220,390-212,993-208,898-204,649-200,502-196,370-192,191-188,027-184,251-177,729-173,046-170,471-166,173-158,121-148,1150-129,364-119,156-108,887-101,500-98,758-88,572-81,392-76,702-71,321-70,242-67,043000000000000000000000000
   Accumulated Other Comprehensive Income 
0
0
0
0
0
0
-1,251
-1,072
-1,058
0
0
0
0
0
0
0
-222
0
0
0
-260
-260
0
0
-349
0
0
0
-534
-560
-644
-733
-855
-1
3
-5
-11
-14
-14
-15
-2,071
-2,279
-2,176
-2,352
-2,110
-1,266
-1,308
-1,351
-2,604
-2,724
-2,838
-2,953
0
-67
-10
16
-142
-748
-982
-779
-395
-76
-431
-407
-67
-67-407-431-76-395-779-982-748-14216-10-670-2,953-2,838-2,724-2,604-1,351-1,308-1,266-2,110-2,352-2,176-2,279-2,071-15-14-14-11-53-1-855-733-644-560-534000-34900-260-260000-2220000000-1,058-1,072-1,251000000
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
87,433
87,993
88,649
89,054
89,740
112,133
116,875
156,356
157,585
160,313
161,931
0
167,891
168,812
169,694
174,427
179,547
182,402
201,721
201,999
202,268
207,653
210,706
212,463
217,173
219,806
247,528
260,807
361,820
363,350
383,611
384,551
400,503
0
402,710
403,822
404,834
405,898
407,479
0
0
00407,479405,898404,834403,822402,7100400,503384,551383,611363,350361,820260,807247,528219,806217,173212,463210,706207,653202,268201,999201,721182,402179,547174,427169,694168,812167,8910161,931160,313157,585156,356116,875112,13389,74089,05488,64987,99387,433000000000000000000000000
   Treasury Stock00000000000000000000000000000000000000000000000000000000000000000
   Other Stockholders Equity 
0
0
0
-3,154
-5,448
-5,448
19,304
20,297
20,613
0
0
0
0
0
37,120
38,690
39,582
40,430
53,694
53,840
0
57,630
59,126
87,141
87,782
87,993
88,649
89,054
90,273
112,692
117,519
157,089
158,440
160,313
161,931
166,338
167,891
168,812
169,694
174,427
181,618
184,681
203,897
204,351
204,377
207,315
210,649
212,648
218,805
221,851
247,601
261,357
359,649
361,559
382,366
383,885
400,364
401,655
402,710
403,822
404,834
405,898
407,479
408,434
409,343
409,343408,434407,479405,898404,834403,822402,710401,655400,364383,885382,366361,559359,649261,357247,601221,851218,805212,648210,649207,315204,377204,351203,897184,681181,618174,427169,694168,812167,891166,338161,931160,313158,440157,089117,519112,69290,27389,05488,64987,99387,78287,14159,12657,630053,84053,69440,43039,58238,69037,1200000020,61320,29719,304-5,448-5,448-3,154000



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue488
Cost of Revenue-398
Gross Profit9090
 
Operating Income (+$)
Gross Profit90
Operating Expense-45,502
Operating Income-45,412-45,412
 
Operating Expense (+$)
Research Development32,857
Selling General Administrative13,043
Selling And Marketing Expenses398
Operating Expense45,50246,298
 
Net Interest Income (+$)
Interest Income3,801
Interest Expense-0
Other Finance Cost-0
Net Interest Income3,801
 
Pretax Income (+$)
Operating Income-45,412
Net Interest Income3,801
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-41,441-49,383
EBIT - interestExpense = -45,412
-41,441
-41,441
Interest Expense0
Earnings Before Interest and Taxes (EBIT)-45,412-41,441
Earnings Before Interest and Taxes (EBITDA)-45,014
 
After tax Income (+$)
Income Before Tax-41,441
Tax Provision-0
Net Income From Continuing Ops-40,801-41,441
Net Income-41,441
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses45,900
Total Other Income/Expenses Net3,971-3,801
 

Technical Analysis of Cardiff Oncology Inc
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Cardiff Oncology Inc. The general trend of Cardiff Oncology Inc is BULLISH with 71.4% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Cardiff Oncology Inc's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (71.4%) Bearish trend (-71.4%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Cardiff Oncology Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 6.06 < 6.38 < 6.42.

The bearish price targets are: 3.41 > 3.31 > 2.79.

Tweet this
Cardiff Oncology Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Cardiff Oncology Inc. The current mas is .

The long score for the Moving Averages is 12/14.
The longshort score for the Moving Averages is 10/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Cardiff Oncology Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Cardiff Oncology Inc. The current macd is 0.17754457.

The long score for the Moving Average Convergence/Divergence (MACD) is 1/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -2/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Cardiff Oncology Inc price going down in the near term. -2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Cardiff Oncology Inc. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Cardiff Oncology Inc price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Cardiff Oncology Inc Daily Moving Average Convergence/Divergence (MACD) ChartCardiff Oncology Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Cardiff Oncology Inc. The current adx is 38.13.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -3/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Cardiff Oncology Inc shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX > 25 && ADX trending down: The ADX is above 25 and indicates a strong bearish trend. The ADX is declining, the bearish trend is weakening. Could be a potential reversal to the upside. -2
Cardiff Oncology Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Cardiff Oncology Inc. The current sar is 6.332088.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Cardiff Oncology Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Cardiff Oncology Inc. The current rsi is 41.81. The current phase is Correction in bull market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -4/(-13 +13).

  • Correction in bull market: Moderate price decline, potential pause in the uptrend. Reassess the market, wait for signs of stabilization.
  • Trending down: The RSI is trending down. -1
Cardiff Oncology Inc Daily Relative Strength Index (RSI) ChartCardiff Oncology Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Cardiff Oncology Inc. The current phase is Oversold in bull market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -6/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Cardiff Oncology Inc price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Cardiff Oncology Inc Daily Stochastic Oscillator ChartCardiff Oncology Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Cardiff Oncology Inc. The current cci is -212.18656233.

The long score for the Commodity Channel Index (CCI) is 0/1.
The longshort score for the Commodity Channel Index (CCI) is -1/(-1 +1).

  • CCI < -100: The CCI is below -100, it indicates that the price is significantly below its average, suggesting a potential oversold condition. -1
Cardiff Oncology Inc Daily Commodity Channel Index (CCI) ChartCardiff Oncology Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Cardiff Oncology Inc. The current cmo is -37.4184809.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Cardiff Oncology Inc Daily Chande Momentum Oscillator (CMO) ChartCardiff Oncology Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Cardiff Oncology Inc. The current willr is -92.20183486.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
Cardiff Oncology Inc Daily Williams %R ChartCardiff Oncology Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Cardiff Oncology Inc.

Cardiff Oncology Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Cardiff Oncology Inc. The current atr is 0.60001393.

Cardiff Oncology Inc Daily Average True Range (ATR) ChartCardiff Oncology Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Cardiff Oncology Inc. The current obv is 64,064,680.

Cardiff Oncology Inc Daily On-Balance Volume (OBV) ChartCardiff Oncology Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Cardiff Oncology Inc. The current mfi is 36.67.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Cardiff Oncology Inc Daily Money Flow Index (MFI) ChartCardiff Oncology Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Cardiff Oncology Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-27STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-28STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-11-29STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-30WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-05STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-13STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-15CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2023-12-18STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-12-20BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2023-12-21STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-22STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-26STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2023-12-27RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2023-12-28STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-29SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-01-02STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-04SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-05RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-08STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-10STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-11RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2024-01-17MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-19DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-24STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-25WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-29STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-30CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-31STOCH LONG EXITThe %K line crosses below the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-01SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-02-05SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-06MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-08STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-09WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-12STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-13STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-14CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-16STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-20MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-02-21CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-22CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-23CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-26STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-28CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-02-29STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-01MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-03-04ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-07STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-08STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-12ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-13STOCH LONG EXITThe %K line crosses below the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-18SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-03-22SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-03-26RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-27STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-28MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-01STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-02STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-04STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-05CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-04-08STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-10STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-11STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-15CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-16DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-17STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-18STOCH LONG EXITThe %K line crosses below the %D line.

6.3. Candlestick Patterns

Cardiff Oncology Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Cardiff Oncology Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5041.806
Ma 20Greater thanMa 505.439
Ma 50Greater thanMa 1003.954
Ma 100Greater thanMa 2002.711
OpenGreater thanClose4.430
Total4/5 (80.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Cardiff Oncology Inc with someone you think should read this too:
  • Are you bullish or bearish on Cardiff Oncology Inc? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Cardiff Oncology Inc? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Cardiff Oncology Inc

I send you an email if I find something interesting about Cardiff Oncology Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Cardiff Oncology Inc.

Receive notifications about Cardiff Oncology Inc in your mailbox!